linjc16/ctgov huggingface dataset:
Increase of Handgrip Strength After the Use of Removable Partial Dentures.

Study Overview
=================
Brief Summary
-----------------
A common goal of the health professions is to keep the elderly functional, preventing sarcopenia and frailty. Is there an association between handgrip strength in partially edentulous elderlies after completing their dentition with removable partial dentures?

Detailed Description
-----------------
A common goal of the health professions is to keep the elderly functional, preventing sarcopenia and frailty. Is there an association between handgrip strength in partially edentulous elderlies after completing their dentition with removable partial dentures?

Official Title
-----------------
Increase of Handgrip Strength After the Use of Removable Partial Dentures.

Conditions
-----------------
Sarcopenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: agree to participate by signing the voluntary informed consent form qualify according to the Eichner Index in any of the categories that represent the loss of premolars and molars: B3-B4-C1-and C2. Exclusion Criteria: not accepting to participate cognitive or auditory sensory impairment- being dependent in activities of daily living belonging to another category of the Eichner Index

Ages Eligible for Study
-----------------
Minimum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Handgrip strength | role of use of removable partial dentures (RPD) in handgrip strength in octogenarians | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
removable partial dentures
Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effect of certain variables such as the fullness of the patients bladder and the position of the treatment applicator on the dose of radiation that other organs such as the bladder and the rectum receive during radiation treatment for endometrial carcinoma.

Detailed Description
-----------------
This study is separated into 2 phases. In phase 1, patients will be asked to have their bladder full for the second planned insertion of the brachytherapy applicator and empty for the third insertion. For phase 2, the effect of cylinder angle on normal tissue dosimetry will be investigated. Of the two bladder states assessed in phase 1 (empty or full), the one deemed to give the lower dose to the total amount of bladder tissue will be considered the standard and applied to all patients in phase 2. In phase 1, to standardize bladder filling, patients will be asked to empty their bladder, then to drink 32 oz of water one and a half hours before the CT scan. The patient will undergo a treatment-planning scan after the brachytherapy cylinder is inserted and before brachytherapy treatment. In phase 2, patients will be asked to fill or empty their bladder according to the results of phase 1. The vaginal cylinder will be placed horizontally for the second treatment. The cylinder will then be angled at a specific angle for the subsequent treatment. A history and physical exam will be performed within 2 weeks of study entry, then at 14 days, 90 days, and 180 days following the completion of therapy.

Official Title
-----------------
Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma

Conditions
-----------------
Cervix Cancer, Endometrial Carcinoma, Carcinoma of the Uterus

Intervention / Treatment
-----------------
* Procedure: Radiation therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologic documentation of carcinoma of the uterus, post-hysterectomy stages I-IVA or vaginal cuff recurrence. Or post-hysterectomy cervix cancer stages IA or IB or post hysterectomy vaginal cancer stage I. ECOG performance status of less than or equal to 2 18 years of age or older Exclusion Criteria: Distant metastases Inoperable disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Radiation therapy|Given as standard therapy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dosimetric analysis, vaginal cuff brachytherapy
Semiquantitative Urine Pregnancy Test Results At ≥9 Weeks of Gestation

Study Overview
=================
Brief Summary
-----------------
Purpose of study is to obtain data on urinary HCG concentrations at >9 weeks of gestation.

Conditions
-----------------
Pregnancy

Intervention / Treatment
-----------------
* Other: NO intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant at >9 weeks of gestation Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: NO intervention|This study was a cross-sectional study. It had no intervention.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urine HCG concentration |  | 1 day |
Salivary Proteome and Sensitivity to Bitterness

Study Overview
=================
Brief Summary
-----------------
This study aims to establish whether the protein composition of healthy males contribute to their sensitivity to the bitterness of caffeine.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: caffeine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy volunteers Exclusion Criteria: smokers currently suffering from oral pathologies sensory aversion to bitterness

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: caffeine<br> | Other: caffeine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sensitivity to caffeine
Airway Responses to Montelukast and Desloratadine.

Study Overview
=================
Brief Summary
-----------------
Montelukast (for asthma) and desloratadine (for allergies) are effective therapy for their current uses. Part of what happens when your allergies trigger your asthma should be prevented by either of these drugs. This project is being conducted to determine if these drugs are effective, either alone or in combination, on controlling asthma that is triggered by allergies.

Official Title
-----------------
Airway Responses to Montelukast and Desloratadine.

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Montelukast (10mg) and Desloratadine (5mg)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: baseline FEV1 > or = 65% predicted positive methacholine challenge (i.e. methacholine PC20 < or = 16mg/ml positive allergen challenge Exclusion Criteria: negative skin prick test lung condition/disease other than asthma currently use montelukast and/or desloratadine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Montelukast (10mg) and Desloratadine (5mg)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Late asthmatic response (maximum percent decrease in FEV1) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Early asthmatic response (maximum percent decrease in FEV1 |  |  | 
| Changes in sputum cell/mediator content |  |  | 
| Changes in airway hyperresponsiveness (methacholine PC20) |  |  |
Efficacy and Safety of Bromfenac Ophthalmic Solution

Study Overview
=================
Brief Summary
-----------------
This is a safety and efficacy study of bromfenac ophthalmic solution

Conditions
-----------------
Cataract Surgery

Intervention / Treatment
-----------------
* Drug: bromfenac ophthalmic solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female greater than or equal to 18 years of age, and scheduled for cataract surgery Exclusion Criteria: Active corneal pathology in either eye

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bromfenac Ophthalmic Solution 0.18%<br> | Drug: bromfenac ophthalmic solution<br>* sterile opthalmic solution<br>|
| Experimental: Xibrom 0.09%<br> | Drug: bromfenac ophthalmic solution<br>* sterile opthalmic solution<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero | Participants with SOIS of 1. Scale: 0=0 cells (complete absence); 0.5=1-5 cells (trace); 1=6-15 cells (very slight); 2=16-25 cells (moderate); 3=26-50 cells (marked); 4=>50 cells (intense) | Day 15 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants That Are Pain Free | Participant description of being pain free taken from patient questionnaire with multiple possible responses | Day 1 |
Clinical Evaluation of a New Viscoelastic for Cataract Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and effectiveness of a new opthalmic viscoelastic material for the use in cataract surgery. The new viscoelastic will be compared to a currently marketed viscoelastic material.

Official Title
-----------------
Clinical Evaluation of a New Viscoelastic for Cataract Surgery

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Device: Vitrax II
* Device: Viscoat


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Otherwise healthy eye with no pathology other than the presence of cataract Visual potential of 20/40 or better Exclusion Criteria: Taking any medications that affect vision, intraocular pressure or ease of cataract surgery (e.g. flomax, glaucoma medications, etc.) Known intraocular pressure increases from steroid treatment Low endothelial cell count

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vitrax II<br>Investigational dispersive viscoelastic | Device: Vitrax II<br>* Viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber.<br>|
| Active Comparator: Viscoat<br>Marketed control dispersive viscoelastic | Device: Viscoat<br>* Currently marketed viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber..<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of Intraocular Pressure Spikes 30 mm Hg or Greater Postoperatively | Cumulative rate of Intraoperative Pressure (IOP) spikes 30 mm Hg (millimeters of mercury) or greater measured postoperatively through three months. | 3 months postoperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative Mean Endothelial Cell Count | mean endothelial cell count (measured by Konan specular microscope) at 3 months | 3 months postoperative |
Requests for Euthanasia and Assisted Suicide

Study Overview
=================
Brief Summary
-----------------
The study epiDESA2 identifies all explicit requests for euthanasia or assisted suicide expressed by the person him/herself, regardless of which professional is asked and regardless of where the request is made (primary care, health institutions, medico-social institutions including nursing home care or at home) in the Burgundy-Franche-Comté region during six months.

Official Title
-----------------
Requests for Euthanasia and Assisted Suicide : Epidemiological Study Conducted as Part of the Establishment of a Structured Network

Conditions
-----------------
Suicide, Assisted

Intervention / Treatment
-----------------
* Other: Questionnaires completion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any adult : Living at home, or in medico-social institutions or hospitalized in primary care or health institutions of Burgundy-Franche-Comté, At the end of life due to advanced stage disease or a major change in the state of health of an elderly person, Who expressed an explicit request for euthanasia or assisted suicide, Who expressed their no objection to the collection of their datas, Who are covered by the French social security system. Exclusion Criteria: They are underage The request was expressed by another person The request is not an explicit request The request appears in the context of a situation other than illness or a general change in state of health The patient is mentally confused

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Questionnaires completion|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Census of requests for euthanasia or assisted suicide in Burgundy-Franche-Comté |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Palliative Care, Euthanasia, Epidemiologic Studies
Use of Low Sensitivity Pregnancy Test for Self-assessment of Medical Abortion

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to design a self-assessment package that could be the preferred option to a follow-up visit at the clinic by the majority of women having early medical abortion.

Official Title
-----------------
The Feasibility of Replacing In-person Follow-up for Early Medical Abortion With a Low Sensitivity Pregnancy Test, Symptom Checklist and Text Messages in the South African Public Sector Setting.

Conditions
-----------------
Completion of Medical Abortion

Intervention / Treatment
-----------------
* Behavioral: Baseline verbal instruction on LSUPT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Already be signed up to do a medical abortion at this clinic Be willing to come to all clinic appointments and be accessible by phone for 2 weeks after sign up for the study Own a cellphone to which will be sent medical abortion-related information and messaging. Exclusion Criteria: 1. Be doing a medical abortion due to failed natural miscarriage 2. Not have a working cellphone -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Demonstration of LSUPT at baseline<br>This group conduct a LSUPT on their own urine sample at baseline with assistance from a fieldworker. | |
| Active Comparator: Baseline verbal instruction of LSUPT<br>Verbal instruction on how to do LSUPT at baseline | Behavioral: Baseline verbal instruction on LSUPT<br> <br> * Other names: Low sensitivity urine pregnancy test;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accurate self-assessment of medical abortion using a low sensitivity pregnancy test | Participants will be randomized to 2 groups. Women in Group A will conduct a baseline low sensitivity urine pregnancy test (LSUPT) on their own urine specimen at their clinic visit with help from the fieldworker. Group B will receive a standardized set of verbal instructions on how to do the test. Both groups will do a LSUPT at home on Day 12. | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
feasibility, self assessment, medical abortion, low sensitivity urine pregnancy test, South Africa
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer

Study Overview
=================
Brief Summary
-----------------
To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer.

Detailed Description
-----------------
To test the combination of oxaliplatin chemotherapy in combination with taxotere chemotherapy in patients with advanced bladder cancer who have failed one prior chemotherapy.

Official Title
-----------------
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer

Conditions
-----------------
Bladder Cancer

Intervention / Treatment
-----------------
* Drug: Oxaliplatin
* Drug: Taxotere


Participation Criteria
=================
Eligibility Criteria
-----------------
Patient Population Type: Advanced Muscle Invasive Bladder Cancer Prior Therapy: One prior therapy for advanced disease Disease: Measurable disease ECOG Performance: 0,1 Indication: Histologically Proven Carcinoma of the bladder For female patient of childbearing potential, neither pregnant nor breastfeeding, and under active contraception Allergies: No known allergy to one of the study drugs Patient Status: No CNS metastases No peripheral neuropathy > grade1 No other serious concomitant illness Fully recovered from any prior therapy Informed Consent: Patient and doctor have signed informed consent Lower Age Limit: Lower age limit >18 Upper Age Limit: Upper Age Limit <70 ANC: ANC >1500/mm3 or WBC > 3000/mm3 Platelets: Platelets >100,000/mm3 Creatinine: Creatinine <1.8mg/dL Bilirubin: Bilirubin <=2.0 x ULN SGPT: SGPT (ALT) <=1.5 x ULN (<4xULN if liver metastases present) RBC: Hemoglobin > 9.0g/dL Cardiovascular: No active congestive heart failure, no uncontrolled angina, no myocardial infarction within the past 6 months Patients with metastatic cancer of the urothelial tract (TCC, Adenocarcinoma) No prior exposure to Oxaliplatin No cytotoxics or radiation 4 weeks prior to enrolling on protocol PT/PTT normal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Oxaliplatin|Calculated per patient|
|Drug: Taxotere|Calculated per patient|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tolerability of the this combination in patients with recurrent metastatic bladder cancer. |  | 1 year |